Why ADEMEDUS FPO'S price plunge might be a golden opportunity

This small biotech has some big potential.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they're material to our investing thesis.

What: Shares of diversified healthcare business ADEMEDUS FPO (ASX: AHZ) dropped more than 10% to 11 cents today. This is because it announced completion of a capital raising to local and international funds and sophisticated investors for $8 million at 10 cents per share. Retail shareholders on the register at May 9 have the opportunity to invest at the same price via a Share Purchase Plan.

 So what: The company is raising funds for three main activities.

  1. To increase its global sales force charged with growing sales of its key, CardioCel, heart defect product. With the product now being sold in the U.S and European Union the company wants to accelerate the rollout and marketing effort to grow revenues.
  2. To fund development of additional applications for CardioCel in the repair and reconstruction of cardiovascular defects and diseases.
  3. To fund Phase II studies into a therapeutic vaccine for treatment of the Herpes Simplex Virus (HSV-2) and Human Papillomavirus (HPV).

Now what: Management remains optimistic about the sales potential of its CardioCel product and chief operating officer, Dr. Julian Chick said: "Currently we are in 8 centres in Europe and have the initial sales in the U.S., with a goal of being in 15 key centres within 12 months. This will provide a platform to expand into other cardiovascular centres globally".

The next 12 to 36 months look exciting for Admedus investors with potential for its CardioCel product to take-off and generate some serious revenues. The therapeutic vaccines remain in the early stages, but dangle an additional carrot to long-term investors, who should look to purchase as close as possible to the 10 cent placement price.

Companies like Admedus are high risk in nature and should only comprise a very small part of your portfolio. Those looking for safer growth potential should consider established healthcare businesses like CSL Limited (ASX: CSL) or Cochlear Limited (ASX: COH).

Motley Fool contributor Tom Richardson owns shares in Admedus. You can find him on Twitter @tommyr345

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »